title: Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.
abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
authors.affiliation: Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Beijng 100044, China.
authors.forename: Meng
authors.initials: M
authors.lastname: Lv
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000367:Age Factors; D002681:China; D006086:Graft vs Host Disease / Q000517:prevention & control / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000208:ethnology / Q000379:methods* / Q000639:trends*; D006801:Humans; D008954:Models, Biological; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous